Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC

Video

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

The two arms on this trial were similar — about 40% of patients on both arms were Asian. Most patients received gemcitabine or docetaxel.

The primary endpoint on this trial, overall survival, was not improved. Progression-free survival and response rates were similar between the two arms.

<<<

View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology

Related Videos
Arutha Kulasinghe, PhD
Andrea Billè, MD
Experts on lung cancer
Experts on lung cancer
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Joachim G. J. V. Aerts, MD, PhD
Alessandro Di Federico, MD
Expert on SCLC
Dazhi Liu, PharmD, MS, BCOP
Stephen V. Liu, MD
Related Content